Viscosity of Fibre Predicts Cholesterol-lowering in Healthy Individuals
Viscosity Rather Than Quality of Dietary Fibre Predicts Cholesterol-lowering Effect in Healthy Individuals
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
-healthy individuals
Exclusion Criteria:
- regular alcohol consumption
- regular smoking
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: High Viscosity
viscous fibre blend added to breakfast cereals consumed in the context of a typical North American diet for 3 weeks duration
|
High viscosity viscous fiber blend sprinkled on wheat and maize bran cereals(Bran Buds®; Kellogg Company)
|
|
EXPERIMENTAL: Medium Viscosity
Kellogg's Bran buds with psyllium breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
|
Bran Buds cereal (white bran and maize bran) with psyllium (Bran Buds® with PSY; Kellogg Company)
|
|
EXPERIMENTAL: Low Viscosity
Kellogg's All Bran breakfast cereal consumed in the context of a typical North American diet for 3 weeks duration
|
All Bran cereal (All Bran®; Kellogg Company)
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in LDL cholesterol
Time Frame: change from baseline after 21 days, relative to control
|
change from baseline after 21 days, relative to control
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
change in total cholesterol
Time Frame: change from baseline after 21 days, relative to control
|
change from baseline after 21 days, relative to control
|
|
change in triglycerides
Time Frame: change from baseline after 21 days, relative to control
|
change from baseline after 21 days, relative to control
|
|
change in HDL cholesterol
Time Frame: change from baseline after 21 days, relative to control
|
change from baseline after 21 days, relative to control
|
|
change in apolipoprotein B
Time Frame: change from baseline after 21 days, relative to control
|
change from baseline after 21 days, relative to control
|
|
change in apolipoprotein A-1
Time Frame: change from baseline after 21 days, relative to control
|
change from baseline after 21 days, relative to control
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ACTUAL)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- viscosity and cholesterol
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.